Vaborbactam (BioDeep_00000802124)
代谢物信息卡片
化学式: C12H16BNO5S (297.0842)
中文名称: 法硼巴坦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: B1(C(CCC(O1)CC(=O)O)NC(=O)CC2=CC=CS2)O
InChI: InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1
描述信息
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D065093 - beta-Lactamase Inhibitors
C2140 - Adjuvant > C183118 - Beta-lactamase Inhibitor
D004791 - Enzyme Inhibitors
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGGdrug: D10998
- PubChem: 56649692
- DrugBank: DB12107
- ChEMBL: CHEMBL3317857
- CAS: 1575712-03-6
- CAS: 1360457-46-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Gabriele Bianco, Matteo Boattini, Sara Comini, Roberto Casale, Marco Iannaccone, Rossana Cavallo, Cristina Costa. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
2022 Apr; 41(4):573-580. doi:
10.1007/s10096-022-04408-5. [PMID: 35061145] - Christina A Sutherland, David P Nicolau. Development of an HPLC Method for the Determination of Meropenem/Vaborbactam in Biological and Aqueous Matrixes.
Journal of chromatographic science.
2020 Aug; 58(8):726-730. doi:
10.1093/chromsci/bmaa041. [PMID: 32685976] - Suzanne L Parker, Saurabh Pandey, Fekade B Sime, Jeffrey Lipman, Jason A Roberts, Steven C Wallis. A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study.
Analytical and bioanalytical chemistry.
2019 Nov; 411(29):7831-7840. doi:
10.1007/s00216-019-02184-4. [PMID: 31732787] - Alexandra M Hanretty, Ishminder Kaur, Alan T Evangelista, Wayne S Moore, Adela Enache, Arun Chopra, Jeffrey J Cies. Pharmacokinetics of the Meropenem Component of Meropenem-Vaborbactam in the Treatment of KPC-Producing Klebsiella pneumoniae Bloodstream Infection in a Pediatric Patient.
Pharmacotherapy.
2018 12; 38(12):e87-e91. doi:
10.1002/phar.2187. [PMID: 30300440] - Young R Lee, Nathaniel T Baker. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
2018 Aug; 37(8):1411-1419. doi:
10.1007/s10096-018-3260-4. [PMID: 29675787] - Christopher M Rubino, Sujata M Bhavnani, Jeffery S Loutit, Elizabeth E Morgan, Dan White, Michael N Dudley, David C Griffith. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.
Antimicrobial agents and chemotherapy.
2018 04; 62(4):. doi:
10.1128/aac.02228-17. [PMID: 29437614] - Christopher M Rubino, Sujata M Bhavnani, Jeffery S Loutit, Brooke Lohse, Michael N Dudley, David C Griffith. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
Antimicrobial agents and chemotherapy.
2018 03; 62(3):. doi:
10.1128/aac.02103-17. [PMID: 29311069] - Keith S Kaye, Tanaya Bhowmick, Symeon Metallidis, Susan C Bleasdale, Olexiy S Sagan, Viktor Stus, Jose Vazquez, Valerii Zaitsev, Mohamed Bidair, Erik Chorvat, Petru Octavian Dragoescu, Elena Fedosiuk, Juan P Horcajada, Claudia Murta, Yaroslav Sarychev, Ventsislav Stoev, Elizabeth Morgan, Karen Fusaro, David Griffith, Olga Lomovskaya, Elizabeth L Alexander, Jeffery Loutit, Michael N Dudley, Evangelos J Giamarellos-Bourboulis. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
JAMA.
2018 02; 319(8):788-799. doi:
10.1001/jama.2018.0438. [PMID: 29486041] - David C Griffith, Jeffery S Loutit, Elizabeth E Morgan, Stephanie Durso, Michael N Dudley. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects.
Antimicrobial agents and chemotherapy.
2016 10; 60(10):6326-32. doi:
10.1128/aac.00568-16. [PMID: 27527080]
